We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.88%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$40.3M
Cap. Flow
-$635M
Cap. Flow %
-22.8%
Top 10 Hldgs %
41.28%
Holding
156
New
21
Increased
23
Reduced
32
Closed
45

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$77.3M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$35.7M
3
NVRO
NEVRO CORP.
NVRO
+$33M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$23.3M
5
AGN
Allergan Inc
AGN
+$22.9M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$46M
2
ABBV icon
AbbVie
ABBV
+$44.3M
3
KITE
Kite Pharma, Inc.
KITE
+$36M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$30.9M
5
WBA
Walgreens Boots Alliance
WBA
+$28.6M

Sector Composition

Rank Sector Weight
1 Healthcare 52.44%
2 Financials 2.69%
3 Technology 0.73%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
26
GSK
GSK
$101B
$24.1M 0.86%
450,640
+130,640
+41% +$7.31M
ALIM
27
DELISTED
Alimera Sciences
ALIM
$22.4M 0.81%
269,722
+146,263
+118% +$11.9M
CBST
28
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$21.2M 0.76%
+210,200
New +$16.3M
ATRS
29
DELISTED
Antares Pharma, Inc.
ATRS
$20.8M 0.75%
8,104,318
+280,700
+4% +$631K
MCK icon
30
McKesson
MCK
$97.7B
$19.1M 0.69%
92,000
-30,000
-25% -$6.09M
GILD icon
31
PUT
Gilead Sciences
GILD
$166B
$18.9M 0.68%
+200,000
New +$20.7M
JUNO
32
DELISTED
Juno Therapeutics, Inc.
JUNO
$18.7M 0.67%
+358,149
New +$16M
LOXO
33
DELISTED
Loxo Oncology, Inc
LOXO
$18.7M 0.67%
1,591,546
– –
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$18.6M 0.67%
655,559
+98,082
+18% +$2.73M
TRUP icon
35
Trupanion
TRUP
$1.16B
$18.6M 0.67%
2,678,176
+1,222,799
+84% +$8.02M
KERX
36
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$16.7M 0.6%
1,183,484
-50,000
-4% -$775K
RMD icon
37
ResMed
RMD
$28.6B
$16.6M 0.6%
+296,300
New +$15.5M
OFIX icon
38
Orthofix Medical
OFIX
$469M
$16M 0.58%
533,812
– –
AMPH icon
39
Amphastar Pharmaceuticals
AMPH
$873M
$14.8M 0.53%
1,276,577
-138,498
-10% -$1.51M
TRIV
40
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$14.4M 0.52%
1,148,575
-383,956
-25% -$5.24M
ARAY icon
41
Accuray
ARAY
$30.1M
$14.1M 0.51%
+1,870,943
New +$13.2M
DYAX
42
DELISTED
DYAX CORPORATION
DYAX
$13.8M 0.5%
982,745
-1,971,939
-67% -$24.7M
IMMU
43
DELISTED
Immunomedics Inc
IMMU
$13.5M 0.48%
2,805,972
– –
TARA icon
44
Protara Therapeutics
TARA
$229M
$13.2M 0.47%
+31,634
New +$12.8M
DBVT
45
DBV Technologies
DBVT
$842M
$13.1M 0.47%
+48,230
New +$12.4M
IMPR
46
DELISTED
IMPRIVATA, INC COM
IMPR
$13M 0.47%
998,252
+27,301
+3% +$378K
NSTG
47
DELISTED
NanoString Technologies, Inc.
NSTG
$12.9M 0.46%
923,378
-80,596
-8% -$981K
LITS
48
Lite Strategy Inc
LITS
$34.4M
$12.6M 0.45%
146,994
+96,404
+191% +$12.7M
HTWR
49
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$12.1M 0.43%
+164,800
New +$12.5M
INGN icon
50
Inogen
INGN
$171M
$11.1M 0.4%
354,330
-198,007
-36% -$4.8M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2014 Portfolio in Review

As of Q4 2014, Deerfield Management held 156 positions worth $2.78B, up 1.5% from $2.74B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deerfield Management withdrew a net $635M in Q4 2014, closing 45 positions and reducing 32 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Achillion Pharmaceuticals worth $35.8M.

  • Deerfield Management's largest Q4 2014 buy was Achillion Pharmaceuticals: 2,920,300 shares worth $35.8M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $77.3M increase.
  • Deerfield Management's biggest Q4 2014 reduction was Kite Pharma, Inc., cutting an estimated $36M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2014, selling an estimated $46M.
  • Deerfield Management's ten largest holdings make up 41% of its $2.78B portfolio in Q4 2014.
  • Deerfield Management opened 21 new positions and closed 45 in Q4 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q4 2014, filed 17 Feb 2015.